By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top ...

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis ...

NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and ...

Novartis Q1 2026 earnings missed as generic competition hit Entresto sales; Kisqali and Pluvicto growth offsets.

Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of ...

Group operating income is down by 12% at US$4.9 billion, below analyst expectations of US$5.1 billion Read more at The ...

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...

(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...